|
|
|
| American Innovation Policy Environment of Pharmaceutical Industry and Its Enlightenment to China ——An Empirical Study on R＆D of Epoetin Alfa |
| Yan Jianzhou, Dong Xinyue, Chen Yongfa, Wang Mengyuan, Shao Rong |
| National Drug Policy and Medical Industry Economy Research Center of China Pharmaceutical University,Nanjing 211198,China |
|
|
|
Abstract This paper presented the American innovation policy environment of pharmaceutical industry.On this basis,case analysis method was used and epoetin alfa(EPO)was taken as the object of empirical study,to discuss the development process of EPO,as well as the action mechanism and implementation effect of the innovation policy environment of American pharmaceutical industry.The results show that Amgen succeeded in achieving complete creation under pharmaceutical innovation policy environment.So China should perfect actively innovation enviornment.Furthermore,the intellectual property protection(IPR)should be strengthened to boost independent R&D positivity,and the awareness of capitalization of technology should be raised to provide diversified ways of raising funds.
|
|
Received: 14 March 2017
|
|
|
|
|
|
[1]曾国屏,苟尤钊,刘磊.从"创新系统"到"创新生态系统"[J].科学学研究,2013,31(1):4-12.
[2]李万,常静,王敏杰,等.创新3.0与创新生态系统[J].科学学研究,2014,32(12):1761-1770.
[3]曹祎遐,高文婧.企业创新生态系统结构发凡[J].产业经济与企业趋势,2015(04):135-141.
[4]刘恒志.创新食品药品机制强化社会管理职能[J].中国食品药品监管,2011(09):51-52.
[5]李中华.美国新药研发的资金来源筹措及其工具[J].中国医药技术经济与管理,2007(01):35-40.
[6]JAYADEV Arjun,STIGLITZ Joseph.Two ideas to increase innovation and reduce pharmaceutical costs and prices[J].Health affairs web exclusives,2008,28(1):165-168.
[7]李晓秋.美国《拜杜法案》的重思与变革[J].知识产权,2009,19(03):90-96.
[8]单美玉,李彩霞,王戴尊,戴磊.《拜杜法案》对美国大学基础研究的影响[J].技术与创新管理,2014,35(06):576-579.
[9]邵蓉,殷天红.美国药品审评付费制度对我国加快药品审评的启示[J].中国药科大学学报,2014,45(03):281-285.
[10]HAFFNER M E,WHITLEY J,MOSE M.Two decades of orphan product development[J].Nat rev drug discov,2002,1(10):821-825.
[11]张延军,王静波,郭剑非.美国孤儿药法案及其对新药研发的影响[J].中国药物经济学,2010(01):27-34.
[12]易八贤,王广平,姬海红,吴晓明.美国孤儿药法案30年历程与我国新药创新制度体系完善[J].中国新药杂志,2014,23(10):1107-1114.
[13]杨莉,刘春艳,张建静,王静.国际药品价格管制方式及效果研究的系统综述[J].中国卫生政策研究,2011,4(07):17-24.
[14]李秀娟,孙利华,刘皓.美国药品价格政策——促进研发与保障消费之间的权衡取舍[J].中国药物经济学,2009(06):41-46.
[15]MERRILL Goozner.The $800 million pill:the truth behind the cost of new drugs[M].University of California Press,2004,53(12):1878-1878.
[16]赵扬,胡豪,王一涛.基于发展中国家相关案例探索我国制药企业产业升级的突破路径[J].中国药房,2011(33):3076-3078. |
|
|
|
2018, Vol. 0 
